Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona (PCCB) Institut de Recerca Hospital Sant Joan de Déu Barcelona Spain
Auto-generated profile, based on publicly available information
Elena Esperanza‐Cebollada
Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona (PCCB) Institut de Recerca Hospital Sant Joan de Déu Barcelona Spain
Summary: B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) comprises multiple subtypes characterized by different genetic alterations. With the use of current standard‐of‐care tests used in clinical practice, 20%–30% of the cases may not be classified into the main genetic subtypes and additional approaches are needed. These patients are grouped in the heterogeneous category B‐other ALL. Transcriptome sequencing (RNA‐seq) has allowed the identification of novel fusion genes and gene expression profiles that define new molecular subtypes. We present RNA‐seq results integrated, in a real‐world scenario, with clinical routine diagnostic data to identify new biomarkers and reclassify a cohort of 60 B‐other ALL patients in the newly described genetic subtypes. Overall, 49 rearrangements were identified, including 32 different fusion genes in 41 B‐other patients (68%). Moreover, we reported six novel rearrangements ( IGK::PAX5 , PAX5::IL1RAPL1 , ETV6::KRT78 , IGH::HIC1 , IGH::MIR100HG and NKAIN4::PNPLA7 ). The integration of RNA‐seq results with standard‐of‐care data allowed us to classify 72% of the patients (43/60) in 11 different subtypes, being DUX4 rearranged and PAX5 alt the most represented subtypes. In summary, RNA‐seq is a reliable tool for the identification of new emerging genetic subtypes contributing to a better genetic risk stratification of BCP‐ALL paediatric patients on the path towards a more personalized medicine.
O(on behalf of the Group of Leukemia of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
on behalf of the Group of Leukemia of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
+22
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology’s complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice.